Story perspectives

FDA Fast-Tracks Daraxonrasib, Doubles Pancreatic Cancer Survival

5/31/2026

38 4

Summary

Story summary

The FDA granted daraxonrasib fast-track status and opened expanded access for metastatic pancreatic cancer patients.
A phase-3 trial of 500 patients showed daraxonrasib doubled median survival to 13.2 months versus 6.7 months with chemotherapy.
Daraxonrasib binds KRAS G12 mutant protein and cyclophilin A, acting as a molecular glue that turns off the signal.
Revolution Medicines will seek FDA approval soon and earned a national-priority review voucher.

1 of 1

Story summary

The FDA granted daraxonrasib fast-track status and opened expanded access for metastatic pancreatic cancer patients.
A phase-3 trial of 500 patients showed daraxonrasib doubled median survival to 13.2 months versus 6.7 months with chemotherapy.
Daraxonrasib binds KRAS G12 mutant protein and cyclophilin A, acting as a molecular glue that turns off the signal.
Revolution Medicines will seek FDA approval soon and earned a national-priority review voucher.